These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

178 related articles for article (PubMed ID: 30322180)

  • 1. Anticancer Activity of Fascaplysin against Lung Cancer Cell and Small Cell Lung Cancer Circulating Tumor Cell Lines.
    Rath B; Hochmair M; Plangger A; Hamilton G
    Mar Drugs; 2018 Oct; 16(10):. PubMed ID: 30322180
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cytotoxic effects of fascaplysin against small cell lung cancer cell lines.
    Hamilton G
    Mar Drugs; 2014 Mar; 12(3):1377-89. PubMed ID: 24608973
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effects of salinomycin and niclosamide on small cell lung cancer and small cell lung cancer circulating tumor cell lines.
    Hochmair M; Rath B; Klameth L; Ulsperger E; Weinlinger C; Fazekas A; Plangger A; Zeillinger R; Hamilton G
    Invest New Drugs; 2020 Aug; 38(4):946-955. PubMed ID: 31446534
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Synergistic cytotoxicity of the CDK4 inhibitor Fascaplysin in combination with EGFR inhibitor Afatinib against Non-small Cell Lung Cancer.
    Plangger A; Rath B; Hochmair M; Funovics M; Neumayer C; Zeillinger R; Hamilton G
    Invest New Drugs; 2022 Apr; 40(2):215-223. PubMed ID: 34596822
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Small cell lung cancer: model of circulating tumor cell tumorospheres in chemoresistance.
    Klameth L; Rath B; Hochmaier M; Moser D; Redl M; Mungenast F; Gelles K; Ulsperger E; Zeillinger R; Hamilton G
    Sci Rep; 2017 Jul; 7(1):5337. PubMed ID: 28706293
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Elevated DNA repair capacity is associated with intrinsic resistance of lung cancer to chemotherapy.
    Zeng-Rong N; Paterson J; Alpert L; Tsao MS; Viallet J; Alaoui-Jamali MA
    Cancer Res; 1995 Nov; 55(21):4760-4. PubMed ID: 7585500
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Non-small and small cell lung carcinoma cell lines exhibit cell type-specific sensitivity to edelfosine-induced cell death and different cell line-specific responses to edelfosine treatment.
    Shafer SH; Williams CL
    Int J Oncol; 2003 Aug; 23(2):389-400. PubMed ID: 12851688
    [TBL] [Abstract][Full Text] [Related]  

  • 8. EHD1 confers resistance to cisplatin in non-small cell lung cancer by regulating intracellular cisplatin concentrations.
    Gao J; Meng Q; Zhao Y; Chen X; Cai L
    BMC Cancer; 2016 Jul; 16():470. PubMed ID: 27411790
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cisplatin-induced apoptosis in non-small-cell lung cancer cells is dependent on Bax- and Bak-induction pathway and synergistically activated by BH3-mimetic ABT-263 in p53 wild-type and mutant cells.
    Matsumoto M; Nakajima W; Seike M; Gemma A; Tanaka N
    Biochem Biophys Res Commun; 2016 Apr; 473(2):490-6. PubMed ID: 26996126
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Fascaplysin Sensitizes Anti-Cancer Effects of Drugs Targeting AKT and AMPK.
    Oh TI; Lee JH; Kim S; Nam TJ; Kim YS; Kim BM; Yim WJ; Lim JH
    Molecules; 2017 Dec; 23(1):. PubMed ID: 29295560
    [TBL] [Abstract][Full Text] [Related]  

  • 11. microRNA-381 suppresses the growth and increases cisplatin sensitivity in non-small cell lung cancer cells through inhibition of nuclear factor-κB signaling.
    Huang RS; Zheng YL; Zhao J; Chun X
    Biomed Pharmacother; 2018 Feb; 98():538-544. PubMed ID: 29287202
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Inhibition of PDGFR by CP-673451 induces apoptosis and increases cisplatin cytotoxicity in NSCLC cells via inhibiting the Nrf2-mediated defense mechanism.
    Yang Y; Deng Y; Chen X; Zhang J; Chen Y; Li H; Wu Q; Yang Z; Zhang L; Liu B
    Toxicol Lett; 2018 Oct; 295():88-98. PubMed ID: 29857117
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Promotion of p53 expression and reactive oxidative stress production is involved in zerumbone-induced cisplatin sensitization of non-small cell lung cancer cells.
    Hu Z; Zeng Q; Zhang B; Liu H; Wang W
    Biochimie; 2014 Dec; 107 Pt B():257-62. PubMed ID: 25220870
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Knockdown of REV3 synergizes with ATR inhibition to promote apoptosis induced by cisplatin in lung cancer cells.
    Jiang HG; Chen P; Su JY; Wu M; Qian H; Wang Y; Li J
    J Cell Physiol; 2017 Dec; 232(12):3433-3443. PubMed ID: 28075014
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Enhanced Anti-Tumor Efficacy of Lipid-Modified Platinum Derivatives in Combination with Survivin Silencing siRNA in Resistant Non-Small Cell Lung Cancer.
    Mattheolabakis G; Ling D; Ahmad G; Amiji M
    Pharm Res; 2016 Dec; 33(12):2943-2953. PubMed ID: 27528390
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Basis for experimental chemotherapy in lung cancer.
    Sadler JG; Natale RB
    Semin Oncol; 1988 Dec; 15(6 Suppl 7):32-6. PubMed ID: 2851175
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prolonged pemetrexed pretreatment augments persistence of cisplatin-induced DNA damage and eliminates resistant lung cancer stem-like cells associated with EMT.
    Tièche CC; Peng RW; Dorn P; Froment L; Schmid RA; Marti TM
    BMC Cancer; 2016 Feb; 16():125. PubMed ID: 26895954
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [DDP-sensitivity-related genes in 10 lung cancer cell lines].
    Li CH; Cai L; Chen XS; Meng QW; Sui GJ
    Zhonghua Zhong Liu Za Zhi; 2008 Jun; 30(6):418-21. PubMed ID: 19024514
    [TBL] [Abstract][Full Text] [Related]  

  • 19. CXCR4 promotes cisplatin-resistance of non-small cell lung cancer in a CYP1B1-dependent manner.
    Xie S; Tu Z; Xiong J; Kang G; Zhao L; Hu W; Tan H; Tembo KM; Ding Q; Deng X; Huang J; Zhang Q
    Oncol Rep; 2017 Feb; 37(2):921-928. PubMed ID: 27922681
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Phloretin exhibits an anticancer effect and enhances the anticancer ability of cisplatin on non-small cell lung cancer cell lines by regulating expression of apoptotic pathways and matrix metalloproteinases.
    Ma L; Wang R; Nan Y; Li W; Wang Q; Jin F
    Int J Oncol; 2016 Feb; 48(2):843-53. PubMed ID: 26692364
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.